Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Gets CLIA Certificate of Compliance

NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has received a CLIA Certificate of Compliance for its Australian lab from the US centers for Medicare and Medicaid Services.

The firm said its lab in Melbourne, where the firm also is based, is the only lab in the Southern Hemisphere with a CLIA Certificate of Compliance. The lab had received CLIA registration in April 2011.

Genetic Technologies markets its BrevaGen test, a risk stratification panel for determining an increased risk for developing breast cancer, to 42 states in the US that don't require additional out-of-state licensure, it said. The firm added that the certificate of compliance clears a path to market the test in the remaining eight states, which includes the key states of California, Florida, and New York.

Genetic Technologies said that launch preparations are underway in Florida and California through its US subsidiary, Phenogen Sciences. It added that the "next significant milestone" for the BrevaGen test is entering the New York market, which will require clearance from the New York State Department of Health.

"The certificate is an essential component of our business strategy, and we are particularly excited to enter Florida and California as these large markets will enable us to potentially improve clinical outcomes for large populations of women who are at risk of developing breast cancer," Genetic Technologies CEO Paul MacLeman said in a statement.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.